Haleon (NYSE:HLN) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded Haleon (NYSE:HLN) from a "hold" to a "buy" in a research report issued Saturday.
• Analysts are mixed but overall positive: two Strong Buy, four Buy, two Hold and one Sell give an average rating of "Moderate Buy" with an average target price of $12.33.
• Market snapshot: HLN opened at $10.08 (down ~1.5%), with a 52-week range of $8.71–$11.42, a market cap of $44.88 billion and a P/E of 25.83.

Haleon (NYSE:HLN - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Saturday.

HLN has been the topic of a number of other research reports. Weiss Ratings restated a "hold (c)" rating on shares of Haleon in a research report on Thursday, January 22nd. Morgan Stanley reiterated an "overweight" rating on shares of Haleon in a report on Monday, December 15th. Jefferies Financial Group reissued a "buy" rating on shares of Haleon in a research note on Tuesday, January 20th. Argus upgraded Haleon to a "strong-buy" rating in a report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft lowered Haleon from a "hold" rating to a "sell" rating in a research report on Monday, January 12th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $12.33.

Haleon Stock Down 1.5%

Shares of NYSE HLN opened at $10.08 on Friday. The firm's fifty day moving average is $10.53 and its 200 day moving average is $9.88. Haleon has a 52 week low of $8.71 and a 52 week high of $11.42. The company has a quick ratio of 0.71, a current ratio of 0.92 and a debt-to-equity ratio of 0.47. The company has a market cap of $44.88 billion, a price-to-earnings ratio of 25.83 and a beta of 0.18.

Institutional Trading of Haleon

Hedge funds and other institutional investors have recently modified their holdings of the business. Parkside Financial Bank & Trust lifted its position in Haleon by 101.3% during the 4th quarter. Parkside Financial Bank & Trust now owns 2,847 shares of the company's stock valued at $29,000 after acquiring an additional 1,433 shares during the period. SOA Wealth Advisors LLC. increased its stake in shares of Haleon by 60.5% during the third quarter. SOA Wealth Advisors LLC. now owns 3,105 shares of the company's stock valued at $28,000 after purchasing an additional 1,170 shares in the last quarter. Citizens National Bank Trust Department increased its stake in shares of Haleon by 167.4% during the third quarter. Citizens National Bank Trust Department now owns 3,276 shares of the company's stock valued at $29,000 after purchasing an additional 2,051 shares in the last quarter. Atlantic Union Bankshares Corp lifted its holdings in shares of Haleon by 293.7% during the third quarter. Atlantic Union Bankshares Corp now owns 3,697 shares of the company's stock valued at $33,000 after purchasing an additional 2,758 shares during the last quarter. Finally, Stance Capital LLC purchased a new position in shares of Haleon during the third quarter valued at approximately $34,000. 6.67% of the stock is owned by hedge funds and other institutional investors.

About Haleon

Haleon plc NYSE: HLN is a global consumer healthcare company formed through the separation of a large pharmaceutical group's consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.